108 Patriot Drive
Suite A
Middletown, DE 19709
United States
(302) 274-8744
https://www.zymeworks.com
版塊: Healthcare
行業: Biotechnology
全職員工: 275
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Mr. Kenneth H. Galbraith C.A. | Chairman, CEO & Interim CFO | 1.04M | 無 | 1963 |
Dr. Paul Moore Ph.D. | Chief Scientific Officer | 872.67k | 無 | 1968 |
Mr. Mark Hollywood | Executive VP and Head of Technical & Manufacturing Operations | 無 | 無 | 1970 |
Mr. Daniel Dex J.D., Ph.D. | Senior VP, Corporate Secretary & General Counsel | 無 | 無 | 無 |
Diana Papove | Senior Manager of Corporate Communications | 無 | 無 | 無 |
Dr. Lindsey Foulkes B.Sc., Ph.D. | Vice President of Corporate Development | 無 | 無 | 無 |
Ms. Laura O'Connor | Vice President of Human Resources & DEI | 無 | 無 | 無 |
Dr. Jeffrey Smith M.D. | Executive VP & Chief Medical Officer | 無 | 無 | 無 |
Dr. Josemund Menezes MBBS | Managing Director of Early-Stage Development for Asia Pacific | 無 | 無 | 無 |
Mr. John Fann Ph.D. | Senior Vice President of Process Sciences | 無 | 無 | 無 |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
截至 2024年5月1日 止,Zymeworks Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中:9;董事會:8;股東權利:7;現金賠償:8。